$2.10
arrow_drop_down5.60%Is ESPR a Buy or Sell based on AI Analysis?
Fundamental Analysis
Based on the fundamental analysis of Esperion Therapeutics, some key indicators are worth noting. Firstly, the company's revenue growth has seen a significant increase of 54.14%, showcasing a positive trend in the company's top-line performance. Additionally, the company has a strong gross margin of 62.67% and operating margin of 52.47%, indicating efficient cost management and profitability. Moreover, Esperion Therapeutics has a high level of debt, with liabilities amounting to $667.36M and debts totaling $548.87M. This high debt level raises concerns about the company's financial health and ability to meet its financial obligations in the long run. Furthermore, the company's negative return on equity of -260.79% and return on assets of -6.94% reflect poor performance in utilizing shareholder equity and assets to generate profits. These indicators suggest potential risks associated with investing in Esperion Therapeutics.
Positive Development
Esperion Therapeutics has sold its European royalty on Bempedoic Acid products for $304.7 million. This deal will provide increased operational and financial flexibility and strategically leverages an asset to unencumber the company's balance sheet. The company retains the rights to receive all potential future milestones of up to $300 million based on commercial performance from its exclusive European licensee, Daiichi Sankyo Europe. This means the company will continue to receive revenue from this partnership.
Negative Development
The company's stock price has been trending downwards in recent weeks, indicating potential investor concern. The company has significant long-term debt, which could potentially hinder its financial flexibility and profitability.
Technical Analysis
Esperion Therapeutics (ESPR) has a neutral technical rating, with one buy indicator (ATR) and five hold indicators (RSI, MACD, CCI, ADX, and ROC) for the month of June 2024. The stock's price has shown a 8.26% increase over the past seven days and a 5.36% increase over the past month. However, its three-month and six-month price change percentages are -18.06% and -19.18% respectively, indicating a recent downward trend in the stock price. The stock's fifty-two week high is $3.4 and the low is $0.7, with a current price of $2.36 as of July 3, 2024. Additionally, Esperion Therapeutics has a technical sell indicator count of two (WILLR and STOCHRSI) for the month of June 2024. The stock's long-term trendline has shown an upward slope, with the longest trendline forecasting a price increase from $0.7 to $0.81 over a period of 170 days. The stock has a beta of 0.99, indicating that it is slightly less volatile than the market overall. Despite recent price fluctuations, Esperion Therapeutics has a strong market score of 69 and industry score of 71, suggesting that it is well-positioned within the healthcare sector.
Conclusion and recommendation
Based on the data provided, Esperion Therapeutics (ESPR) is currently trading at $2.36 with a market cap of $443.34M. The company operates in the healthcare sector and has shown a 54.14% revenue growth, indicating positive performance. However, the company has a negative return on equity of -260.79% and a negative net income of -$209.25M, suggesting financial struggles. The stock has a neutral technical rating and a high fifty-two-week low price change percent of 237.14%, which may indicate volatility. It is important to note that Esperion Therapeutics does not pay dividends and has a high debt-to-equity ratio, which could raise concerns for investors. In conclusion, while Esperion Therapeutics has shown strong revenue growth, the company's negative financial indicators and high debt levels present risks for investors. With a neutral analyst recommendation and a negative return on equity, caution is advised when considering investing in ESPR. It is important for investors to closely monitor the company's financial performance and market trends before making any investment decisions. Additionally, the high volatility of the stock and lack of dividend payments may not be suitable for all investors, and further research and analysis are recommended before taking any positions in Esperion Therapeutics.